Ferritin and LDH predict thrombotic risk beyond conventional scoring systems in DLBCL.
4 affiliations
- 1Medicapoint Gaziantep Hospital, Department of Hematology, Gaziantep, Turkey. [email protected].
- 2Etlik City Hospital, Department of Hematology, Ankara, Turkey.
- 3Ministry of Health Hitit University, Erol Olçok Training and Research Hospital, Çorum, Turkey.
- 4Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Department of Hematology, Istanbul, Turkey.
Abstract
Thrombotic events are clinically significant complications in diffuse large B-cell lymphoma (DLBCL) that adversely affect treatment continuity and outcomes. Despite their importance, no standardized predictive approach exists, and traditional cancer-associated thrombosis models perform suboptimally in hematological malignancies. We retrospectively analyzed 133 adult patients with DLBCL treated at a single center between 2009 and 2021. Thrombotic events required objective radiological confirmation. Baseline demographic, clinical, and laboratory parameters were compared between patients with and without thrombosis. ROC analysis determined the optimal ferritin cutoff, and Cox proportional hazards and Fine-Gray competing-risk models (with death as a competing event) identified independent predictors. Thrombosis occurred in 16 patients (12.0%), all venous. Baseline clinical characteristics and the Khorana score did not differ between groups. Patients with thrombosis had significantly higher ferritin (median 331.5 vs. 113 ng/mL; p = 0.026) and LDH (median 459.5 vs. 256 U/L; p = 0.022). ROC analysis identified a ferritin cutoff of ≥ 227 ng/mL (AUC 0.686, 95% CI 0.532-0.840), associated with a 6.1-fold increased risk (OR 6.10, 95% CI 1.75-21.28). In multivariate Cox regression, ferritin ≥ 227 ng/mL (HR 3.77, 95% CI 1.13-12.60, p = 0.031) was an independent predictor and remained significant in competing-risk analysis (sHR 4.68); LDH was significant in Cox analysis (HR 1.002 per unit increase, p = 0.034) but was attenuated in the competing-risk model. In DLBCL, where no standardized thrombosis risk-stratification approach exists, elevated ferritin at diagnosis independently predicted thrombotic events, while LDH was significant in univariate analysis. These readily available parameters may contribute to lymphoma-specific thrombosis scoring systems and warrant prospective validation.
Related
- Artificial Intelligence Versus Conventional Scoring for Assessing Small Bowel Capsule Endoscopy Cleanliness in Crohn's Disease
- A non-invasive simplified scoring system to predict airway mucus plugs in asthma.
- Derivation of a clinical-radiological scoring system to predict foreign body aspiration in children
- A preoperative scoring model to predict intraoperative high end-tidal carbon dioxide in endoscopic resection of gastric submucosal tumors
- Prognostic value of scoring systems in geriatric patients receiving warfarin presenting with upper gastrointestinal bleeding
BibTeX
@article{saglam2026ferritin,
title = {{Ferritin and LDH predict thrombotic risk beyond conventional scoring systems in DLBCL.}},
author = {Buğra Sağlam and Murat Albayrak and Abdulkerim Yıldız and Pınar Tığlıoğlu and Mesut Tığlıoğlu and Merih Reis Aras and Fatma Yılmaz and Hatice Berna Afacan Öztürk},
journal = {Annals of hematology},
year = {2026},
month = jul,
doi = {10.1007/s00277-026-07201-y},
url = {https://europepmc.org/article/MED/42897372},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Ferritin and LDH predict thrombotic risk beyond conventional scoring systems in DLBCL.
AU - Buğra Sağlam
AU - Murat Albayrak
AU - Abdulkerim Yıldız
AU - Pınar Tığlıoğlu
AU - Mesut Tığlıoğlu
AU - Merih Reis Aras
AU - Fatma Yılmaz
AU - Hatice Berna Afacan Öztürk
PY - 2026
DA - 2026/07/01
JO - Annals of hematology
DO - 10.1007/s00277-026-07201-y
UR - https://europepmc.org/article/MED/42897372
AB - Thrombotic events are clinically significant complications in diffuse large B-cell lymphoma (DLBCL) that adversely affect treatment continuity and outcomes. Despite their importance, no standardized predictive approach exists, and traditional cancer-associated thrombosis models perform suboptimally in hematological malignancies. We retrospectively analyzed 133 adult patients with DLBCL treated at a single center between 2009 and 2021. Thrombotic events required objective radiological confirmation. Baseline demographic, clinical, and laboratory parameters were compared between patients with and without thrombosis. ROC analysis determined the optimal ferritin cutoff, and Cox proportional hazards and Fine-Gray competing-risk models (with death as a competing event) identified independent predictors. Thrombosis occurred in 16 patients (12.0%), all venous. Baseline clinical characteristics and the Khorana score did not differ between groups. Patients with thrombosis had significantly higher ferritin (median 331.5 vs. 113 ng/mL; p = 0.026) and LDH (median 459.5 vs. 256 U/L; p = 0.022). ROC analysis identified a ferritin cutoff of ≥ 227 ng/mL (AUC 0.686, 95% CI 0.532-0.840), associated with a 6.1-fold increased risk (OR 6.10, 95% CI 1.75-21.28). In multivariate Cox regression, ferritin ≥ 227 ng/mL (HR 3.77, 95% CI 1.13-12.60, p = 0.031) was an independent predictor and remained significant in competing-risk analysis (sHR 4.68); LDH was significant in Cox analysis (HR 1.002 per unit increase, p = 0.034) but was attenuated in the competing-risk model. In DLBCL, where no standardized thrombosis risk-stratification approach exists, elevated ferritin at diagnosis independently predicted thrombotic events, while LDH was significant in univariate analysis. These readily available parameters may contribute to lymphoma-specific thrombosis scoring systems and warrant prospective validation.
SN - 0939-5555
SN - 1432-0584
ER -